Regeneron Pharmaceuticals Inc (REGN) - Net Assets
Based on the latest financial reports, Regeneron Pharmaceuticals Inc (REGN) has net assets worth $31.42 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($40.87 Billion) and total liabilities ($9.45 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check REGN tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $31.42 Billion |
| % of Total Assets | 76.89% |
| Annual Growth Rate | 25.14% |
| 5-Year Change | 66.54% |
| 10-Year Change | 602.52% |
| Growth Volatility | 130.86 |
Regeneron Pharmaceuticals Inc - Net Assets Trend (1990–2025)
This chart illustrates how Regeneron Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. See Regeneron Pharmaceuticals Inc (REGN) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Regeneron Pharmaceuticals Inc (1990–2025)
The table below shows the annual net assets of Regeneron Pharmaceuticals Inc from 1990 to 2025. For live valuation and market cap data, see REGN stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $31.26 Billion | +6.48% |
| 2024-12-31 | $29.35 Billion | +13.02% |
| 2023-12-31 | $25.97 Billion | +14.60% |
| 2022-12-31 | $22.66 Billion | +20.75% |
| 2021-12-31 | $18.77 Billion | +70.23% |
| 2020-12-31 | $11.03 Billion | -0.58% |
| 2019-12-31 | $11.09 Billion | +26.63% |
| 2018-12-31 | $8.76 Billion | +42.53% |
| 2017-12-31 | $6.14 Billion | +38.09% |
| 2016-12-31 | $4.45 Billion | +21.74% |
| 2015-12-31 | $3.65 Billion | +43.76% |
| 2014-12-31 | $2.54 Billion | +30.24% |
| 2013-12-31 | $1.95 Billion | +56.74% |
| 2012-12-31 | $1.25 Billion | +156.39% |
| 2011-12-31 | $485.73 Million | -7.97% |
| 2010-12-31 | $527.82 Million | +33.03% |
| 2009-12-31 | $396.76 Million | -5.27% |
| 2008-12-31 | $418.85 Million | -9.00% |
| 2007-12-31 | $460.27 Million | +112.47% |
| 2006-12-31 | $216.62 Million | +90.02% |
| 2005-12-31 | $114.00 Million | -37.55% |
| 2004-12-31 | $182.54 Million | +32.62% |
| 2003-12-31 | $137.64 Million | -5.71% |
| 2002-12-31 | $145.98 Million | -45.19% |
| 2001-12-31 | $266.36 Million | +46.24% |
| 2000-12-31 | $182.13 Million | +66.33% |
| 1999-12-31 | $109.50 Million | -16.54% |
| 1998-12-31 | $131.20 Million | -5.54% |
| 1997-12-31 | $138.90 Million | +29.93% |
| 1996-12-31 | $106.90 Million | +57.44% |
| 1995-12-31 | $67.90 Million | +1.19% |
| 1994-12-31 | $67.10 Million | -31.81% |
| 1993-12-31 | $98.40 Million | +12.84% |
| 1992-12-31 | $87.20 Million | -17.89% |
| 1991-12-31 | $106.20 Million | +770.49% |
| 1990-12-31 | $12.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Regeneron Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3580410000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $35.80 Billion | 114.53% |
| Common Stock | $100.00K | 0.00% |
| Other Comprehensive Income | $77.50 Million | 0.25% |
| Total Equity | $31.26 Billion | 100.00% |
Regeneron Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Regeneron Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ENGIE ADR/1 EO 1
F:GZFB
|
$63.66 Billion |
|
Shengyi Technology Co Ltd
SHG:600183
|
$63.77 Billion |
|
Lloyds Banking Group plc
F:LLD2
|
$63.81 Billion |
|
Vale S.A
MX:VALEN
|
$63.84 Billion |
|
Petróleo Brasileiro S.A. - Petrobras
SA:PETR3
|
$63.26 Billion |
|
NETEASE INC. O.N.
F:4Y01
|
$62.70 Billion |
|
Air Products and Chemicals Inc
NYSE:APD
|
$62.29 Billion |
|
Larsen & Toubro Limited
NSE:LT
|
$62.28 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Regeneron Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 29,353,600,000 to 31,256,900,000, a change of 1,903,300,000 (6.5%).
- Net income of 4,504,900,000 contributed positively to equity growth.
- Dividend payments of 370,300,000 reduced retained earnings.
- Share repurchases of 3,970,700,000 reduced equity.
- New share issuances of 635,900,000 increased equity.
- Other comprehensive income increased equity by 85,400,000.
- Other factors increased equity by 1,018,100,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.50 Billion | +14.41% |
| Dividends Paid | $370.30 Million | -1.18% |
| Share Repurchases | $3.97 Billion | -12.7% |
| Share Issuances | $635.90 Million | +2.03% |
| Other Comprehensive Income | $85.40 Million | +0.27% |
| Other Changes | $1.02 Billion | +3.26% |
| Total Change | $- | 6.48% |
Book Value vs Market Value Analysis
This analysis compares Regeneron Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.14x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 774.16x to 2.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1990-12-31 | $0.79 | $614.73 | x |
| 1991-12-31 | $6.84 | $614.73 | x |
| 1992-12-31 | $5.66 | $614.73 | x |
| 1993-12-31 | $5.94 | $614.73 | x |
| 1994-12-31 | $3.54 | $614.73 | x |
| 1995-12-31 | $3.44 | $614.73 | x |
| 1996-12-31 | $4.37 | $614.73 | x |
| 1997-12-31 | $4.79 | $614.73 | x |
| 1998-12-31 | $4.23 | $614.73 | x |
| 1999-12-31 | $3.48 | $614.73 | x |
| 2000-12-31 | $5.18 | $614.73 | x |
| 2001-12-31 | $6.33 | $614.73 | x |
| 2002-12-31 | $3.32 | $614.73 | x |
| 2003-12-31 | $2.73 | $614.73 | x |
| 2004-12-31 | $3.25 | $614.73 | x |
| 2005-12-31 | $2.04 | $614.73 | x |
| 2006-12-31 | $3.74 | $614.73 | x |
| 2007-12-31 | $6.94 | $614.73 | x |
| 2008-12-31 | $5.31 | $614.73 | x |
| 2009-12-31 | $4.97 | $614.73 | x |
| 2010-12-31 | $6.36 | $614.73 | x |
| 2011-12-31 | $5.36 | $614.73 | x |
| 2012-12-31 | $10.79 | $614.73 | x |
| 2013-12-31 | $17.54 | $614.73 | x |
| 2014-12-31 | $22.41 | $614.73 | x |
| 2015-12-31 | $31.72 | $614.73 | x |
| 2016-12-31 | $38.26 | $614.73 | x |
| 2017-12-31 | $53.01 | $614.73 | x |
| 2018-12-31 | $76.28 | $614.73 | x |
| 2019-12-31 | $96.77 | $614.73 | x |
| 2020-12-31 | $95.79 | $614.73 | x |
| 2021-12-31 | $167.28 | $614.73 | x |
| 2022-12-31 | $199.68 | $614.73 | x |
| 2023-12-31 | $228.44 | $614.73 | x |
| 2024-12-31 | $255.03 | $614.73 | x |
| 2025-12-31 | $287.82 | $614.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Regeneron Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.41%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 31.41%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.30x
- Recent ROE (14.41%) is above the historical average (-9.44%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1990 | -27.05% | -66.00% | 0.20x | 2.08x | $-4.52 Million |
| 1991 | -4.24% | -61.64% | 0.06x | 1.07x | $-15.12 Million |
| 1992 | -21.90% | -166.09% | 0.12x | 1.12x | $-27.82 Million |
| 1993 | -40.55% | -376.42% | 0.09x | 1.20x | $-49.74 Million |
| 1994 | -45.75% | -132.33% | 0.25x | 1.40x | $-37.41 Million |
| 1995 | -34.61% | -85.77% | 0.29x | 1.38x | $-30.29 Million |
| 1996 | -30.31% | -134.44% | 0.18x | 1.29x | $-43.09 Million |
| 1997 | -8.35% | -35.05% | 0.20x | 1.21x | $-25.49 Million |
| 1998 | -6.55% | -22.51% | 0.24x | 1.20x | $-21.72 Million |
| 1999 | -21.10% | -66.96% | 0.25x | 1.25x | $-34.05 Million |
| 2000 | -12.75% | -39.16% | 0.28x | 1.14x | $-41.43 Million |
| 2001 | -28.60% | -346.70% | 0.04x | 1.86x | $-102.82 Million |
| 2002 | -85.20% | -565.66% | 0.06x | 2.68x | $-138.98 Million |
| 2003 | -78.07% | -186.89% | 0.12x | 3.48x | $-121.22 Million |
| 2004 | 22.84% | 23.96% | 0.37x | 2.59x | $23.44 Million |
| 2005 | -83.72% | -144.19% | 0.16x | 3.71x | $-106.85 Million |
| 2006 | -47.24% | -161.30% | 0.11x | 2.70x | $-124.00 Million |
| 2007 | -22.94% | -84.46% | 0.13x | 2.03x | $-151.63 Million |
| 2008 | -19.75% | -34.69% | 0.36x | 1.60x | $-124.60 Million |
| 2009 | -17.10% | -17.88% | 0.51x | 1.87x | $-107.51 Million |
| 2010 | -19.79% | -22.76% | 0.42x | 2.06x | $-157.25 Million |
| 2011 | -45.65% | -49.74% | 0.34x | 2.72x | $-270.33 Million |
| 2012 | 60.24% | 54.43% | 0.66x | 1.67x | $625.73 Million |
| 2013 | 21.74% | 20.16% | 0.71x | 1.51x | $229.15 Million |
| 2014 | 13.69% | 12.34% | 0.73x | 1.52x | $93.84 Million |
| 2015 | 17.40% | 15.50% | 0.73x | 1.53x | $270.57 Million |
| 2016 | 20.13% | 18.42% | 0.70x | 1.57x | $450.60 Million |
| 2017 | 19.51% | 20.41% | 0.67x | 1.43x | $584.10 Million |
| 2018 | 27.91% | 36.42% | 0.57x | 1.34x | $1.57 Billion |
| 2019 | 19.08% | 26.91% | 0.53x | 1.34x | $1.01 Billion |
| 2020 | 31.86% | 41.35% | 0.50x | 1.56x | $2.41 Billion |
| 2021 | 43.03% | 50.25% | 0.63x | 1.36x | $6.20 Billion |
| 2022 | 19.14% | 35.64% | 0.42x | 1.29x | $2.07 Billion |
| 2023 | 15.22% | 30.14% | 0.40x | 1.27x | $1.36 Billion |
| 2024 | 15.03% | 31.07% | 0.38x | 1.29x | $1.48 Billion |
| 2025 | 14.41% | 31.41% | 0.35x | 1.30x | $1.38 Billion |
Industry Comparison
This section compares Regeneron Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $296,451,843
- Average return on equity (ROE) among peers: -36.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc (REGN) | $31.42 Billion | -27.05% | 0.30x | $63.33 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $81.00 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.55 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $33.54 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.59 Billion |
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degenera… Read more